Perbedaan Central Proteina Prima Tbk. dan Brigit Biofarmaka Teknologi Tbk.: Central Proteina Prima Tbk. diperdagangkan di Rp50 (kapitalisasi pasar 2,98 T, volume 24 jam 2,22 jt), sedangkan Brigit Biofarmaka Teknologi Tbk. diperdagangkan di Rp246 (kapitalisasi pasar 167,37 M, volume 24 jam 71 rb). Perbedaan utamanya: Central Proteina Prima Tbk. jauh lebih besar — sekitar 17,8× kapitalisasi pasar Brigit Biofarmaka Teknologi Tbk., dan Central Proteina Prima Tbk. lebih aktif diperdagangkan (2,22 jt vs 71 rb). Mana yang lebih baik tergantung tujuan investasimu.
| CPRO | OBAT | |
|---|---|---|
Kapitalisasi Pasar | 2,98 T | 167,37 M |
Volume | 2,22 jt | 71 rb |
Lot | 22,16 rb | 710 |
Perputaran | 110,81 jt | 17,51 jt |
Harga Rata-rata | 50 | 246,63 |
Nilai Transaksi | 110,81 jt | 17,51 jt |
Harga Ekuilibrium Indikatif | 50 | 246 |
Volume Ekuilibrium Indikatif | 32 | 1 |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Central Proteinprima Tbk (The Company) was established on April 30, 1980 based on the Domestic Capital Investment Law No. 6 year 1968. Base on notarial deed no. 45 dated Dec 7, 1989 the company's share holders agreed offering 1.000.000 share to public, increase paid up capital and authorized capital. At 14 May 1990, the company's shares were treadeable in Jakarta Stock Exchange.Base on notarial deed no.7 dated 4 Oct 2004 of Fahiah Helmi, SH, the company was changed to private company. At Nov 5, 2004, base on JSX letter no S-1671/BEJ-PSR/11-2004 the company was delisted. And then at Sep 2004, the Company's ownership was changed to foreign investment. The Company’s articles of association has been amended several times, most recently by notarial deed No. 57 of Lies Herminingsih, S.H., dated Sep 30, 2006, concerning change of director's job description.
Selengkapnya di halaman CPRO →PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Selengkapnya di halaman OBAT →